

020757_5004

APR - 6 1998

NDA 20-757/ S-004

Bristol-Myers Squibb
Attention: Douglas B. Hay, Ph.D.
P.O. Box 4000
Princeton, NJ 08543-4000

Dear Dr. Hay:

Please refer to your March 9, 1998 supplemental new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Avapro (irbesartan) Tablets, 75 mg, 150 mg and 300 mg.


The user fee goal date is September 10, 1998.

The supplemental application provides for the approval of Σ facility as an alternate manufacturer of irbesartan

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

Sincerely yours,



James H. Short, Ph.D.
Acting Chemistry Team Leader, DNDC I
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc: NDA 20-757/ S-004
HFD-110/ DIV FILE
HFD-110/ Rmittal 3/26/98
HFD-110/ Project Manager/ KBongiovanni
HFD-92
DISTRICT OFFICE
HFD-810/ CHOIBERG
cg/03/27/98

Approval Date: September 30, 1997

APPROVAL

APR - 6 1998

DIVISION OF CARDIO-RENAL DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

NDA #: 20-757/SCM-S004

REVIEW DATE: 23-MAR-98

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
SCM-S004	09-MAR-98	10-MAR-98	11-MAR-98

NAME & ADDRESS OF APPLICANT

Bristol Myers Squibb Company
P. O. Box 4000
Princeton, NJ 08543-4000

SUPPLEMENT PROVIDES FOR:

The approval of [] facility as an alternative manufacturer of
irbesartan [] in the synthesis of the irbesartan drug
substance.

SPECIAL SUPPLEMENT - CHANGES BEING EFFECTED

DRUG PRODUCT NAME

<u>Established Name:</u>	Irbesartan
<u>Proprietary:</u>	AVAPRO
<u>Nonproprietary/USAN:</u>	Irbesartan
<u>Code Name/#:</u>	SR 47,436, BMS-186295, BMS-186295-01
<u>Chem.Type/Ther.Class:</u>	1/S

AND Suitability Petition/DESI/Patent Status:


The U.S. Patent 5,270,317 held by Elf Sanofi was issued for irbesartan and is due to expire on March 2011.

PHARMACOL.CATEGORY/INDICATION:	Angiotensin II Receptor Antagonist/Hypertension
DOSAGE FORM:	TABLETS
STRENGTH	75 mg, 150 mg and 300 mg.
ROUTE OF ADMINISTRATION:	ORAL
DISPENSED:	Rx

CHEMICAL NAME 2-Butyl-3-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1,3-diazaspiro[4.4]non-1-en-4-one.

CAS # 138402-11-6 MOLECULAR FORMULA C₂₅H₂₈N₆O MOLECULAR WEIGHT 428.5

STRUCTURAL FORMULA



SUPPORTING DOCUMENTS:

DMF#

RELATED DOCUMENTS (if applicable): NDA 20-758 Irbesartan/Hydrochlorothiazide

CONSULTS: None at present.

REMARKS/COMMENTS:

A request for inspection was submitted on March 23, 1998. As of March 24, 1998, the status of EER is acceptable and a copy of the EER report is attached at the end of this review.

CONCLUSIONS & RECOMMENDATIONS:


Satisfactory and approval is recommended.

cc:

HFD-110/Division File
HFD-110/Ram Mittal/date
HFD-110/CSO

R/D Init by: JShort/

J Short
3-26-98



Ramsharan D. Mittal Ph.D., Review Chemist
fileame: C:\NDA\20757\20757SCM.004

2 Page(s) Withheld

✓ § 552(b)(4) Trade Secret / Confidential

 § 552(b)(5) Deliberative Process

 § 552(b)(5) Draft Labeling

CDEK Establishment Evaluation Report
for March 24, 1998

Page 1 of 1

Application: NDA 20757/004
Stamp: 10-MAR-1998 Regulatory Due: 10-SEP-1998
Applicant: SANOFI PHARMS
90 PARKE AVE
NEW YORK, NY 10016

Priority: 1S
Action Goal:
Brand Name: AVAPRO (IRBESARTAN) TABS
75/150/300 MG
Established Name:
Generic Name: IRBESARTAN TABS 75/150/300MG
Dosage Form: TAB (TABLET)
Strength: 75, 150, 300MG

Org Code: 110

District Goal: 06-JUL-1998

FDA Contacts: K. BONGIOVANNI (HFD-110)
R. MITTAL (HFD-110)
J. SHORT (HFD-110)

301-594-5300 , Project Manager
301-594-5353 , Review Chemist
301-594-5300 , Team Leader

Overall Recommendation:

ACCEPTABLE on 24-MAR-1998 by M. EGAS (HFD-322) 301-594-0095

Establishment:

DMF No:

AADA No:

Profile: CSN OAI Status: NONE
Last Milestone: OC RECOMMENDATION
Milestone Date 24-MAR-1998
Decision: ACCEPTABLE
Reason: BASED ON PROFILE

Responsibilities:

Appears This Way
On Original